Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Shanglong Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5828-4718; OpenAlex author ID A5019213836. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
54
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 3 papers

Papers 19

  1. Predicting Synchronous Liver Metastasis in Pancreatic Cancer Using CT Radiomics and Clinical Features: A Machine Learning Approach. Last author DOI 10.1016/j.acra.2026.08.028↗
  2. Metabolic signatures of lipid dysregulation and inflammation characterize pancreatic cancer risk in type 2 diabetes mellitus and improve risk stratification: a… Co-author DOI 10.1016/j.diabres.2026.113230↗
  3. Metabolic dysfunction-associated steatotic liver disease accelerates pancreatic cancer progression and metastasis via the macrophage migration inhibitory facto… Co-author DOI 10.1038/s41392-025-02562-8↗
  4. KCNH2 regulates the growth and metastasis of pancreatic cancer Co-author DOI 10.1097/jp9.0000000000000123↗
  5. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Last author DOI 10.3389/fonc.2023.1166860↗
  6. Cancer-associated fibroblast-secreted miR-421 promotes pancreatic cancer by regulating the SIRT3/H3K9Ac/HIF-1α axis. Co-author DOI 10.1002/kjm2.12590↗
  7. LINC00960 regulates cell proliferation and glycolysis in pancreatic cancer through the miR-326-3p/TUFT1/AKT-mTOR axis. Co-author DOI 10.1002/kjm2.12594↗
  8. Extracellular vesicle-mediated crosstalk between pancreatic cancer and stromal cells in the tumor microenvironment. Last author DOI 10.1186/s12951-022-01382-0↗
  9. The Interplay Between Inflammation and Stromal Components in Pancreatic Cancer. Last author DOI 10.3389/fimmu.2022.850093↗
  10. The Metabolism Symbiosis Between Pancreatic Cancer and Tumor Microenvironment. Last author DOI 10.3389/fonc.2021.759376↗
  11. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro. First author DOI 10.1016/j.lfs.2020.118523↗
  12. Establishment and application of an artificial intelligence diagnosis system for pancreatic cancer with a faster region-based convolutional neural network. Co-author DOI 10.1097/cm9.0000000000000544↗
  13. Pancreatic stellate cells facilitate pancreatic cancer cell viability and invasion. Co-author DOI 10.3892/ol.2018.9816↗
  14. The regulatory roles of long noncoding RNAs in the biological behavior of pancreatic cancer. Co-author DOI 10.4103/sjg.sjg_465_18↗
  15. Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor /c-Met/survivin regulated by P53/P21. First author DOI 10.1016/j.yexcr.2017.04.027↗
  16. TUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transition. Co-author DOI 10.1016/j.canlet.2016.08.017↗
  17. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Co-author DOI 10.18632/oncotarget.2184↗
  18. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer: a meta-analysis. First author DOI 10.1016/j.pan.2013.01.013↗
  19. Vitamin D status and the risk of pancreatic cancer: a meta-analysis. Co-author DOI 10.3760/cma.j.issn.0366-6999.20122850↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanxiang Zhan · 5 shared papers, 2016–2023 · strength 0.72
  2. Shuai Xiang · 2 shared papers, 2026 · strength 0.63
  3. T. T. Qu · 3 shared papers, 2022–2023 · strength 0.44
  4. Jing‐Hao Lei · 3 shared papers, 2022–2023 · strength 0.44
  5. Weidong Guo · 3 shared papers, 2016–2022 · strength 0.34
  6. Yanbing Zhou · 3 shared papers, 2017–2020 · strength 0.34
  7. Xu Che · 1 shared paper, 2026 · strength 0.32
  8. Yunlong Li · 1 shared paper, 2026 · strength 0.32
  9. Yongxing Du · 1 shared paper, 2026 · strength 0.32
  10. Yuzhe Han · 1 shared paper, 2026 · strength 0.32
  11. Jingyu Cao · 2 shared papers, 2022 · strength 0.28
  12. Xiaopeng Yang · 2 shared papers, 2017–2020 · strength 0.23
  13. Jianfei Xu · 2 shared papers, 2017–2020 · strength 0.23
  14. Ying Li · 1 shared paper, 2023 · strength 0.22
  15. Jing Wang · 1 shared paper, 2023 · strength 0.22
  16. Ying Li · 1 shared paper, 2022 · strength 0.20
  17. Bin Zhou · 2 shared papers, 2016–2022 · strength 0.20
  18. Ying Li · 1 shared paper, 2021 · strength 0.19
  19. Jie Xu · 1 shared paper, 2021 · strength 0.19
  20. Yingxin Wei · 1 shared paper, 2022 · strength 0.19
  21. Ying Li · 1 shared paper, 2022 · strength 0.19
  22. Huan Zhang · 1 shared paper, 2026 · strength 0.19
  23. Chao Gao · 1 shared paper, 2026 · strength 0.19
  24. Qian Yu · 1 shared paper, 2026 · strength 0.19
  25. Ruining Gong · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.